SCHEMBL2033422

SCHEMBL2033422

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1ccc(CBr)nc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
SSTR4 P31391 1/20 0.34
AOC3 Q16853 1/20 0.33
PAX8 Q06710 1/20 0.33
PDPK1 O15530 1/20 0.32
USP30 Q70CQ3 1/20 0.32
MT-CO2 P00403 1/20 0.32
AKT1 P31749 1/20 0.32
F2 P00734 1/20 0.31
MAPKAPK2 P49137 1/20 0.31
KDM4E B2RXH2 2/20 0.30
ALDH1A1 P00352 1/20 0.30
NPC1 O15118 1/20 0.30
MAPT P10636 1/20 0.30
RAB9A P51151 1/20 0.30
CNR2 P34972 1/20 0.30
SOS1 Q07889 1/20 0.30
SYK P43405 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31027448 0.82 AOC3 (0.39) HDAC1HDAC8HDAC6AOC3PAX8
SCHEMBL2641560 0.82 PGK1 (0.37) HDAC1HDAC8HDAC6AOC3PAX8
SCHEMBL17166912 0.81 SSTR4 (0.36) HDAC1HDAC8HDAC6SSTR4PAX8
SCHEMBL16690795 0.79 PDPK1 (0.33) HDAC1HDAC8HDAC6SSTR4PDPK1
SCHEMBL2034907 0.79 HDAC1 (0.37) HDAC1HDAC6SSTR4PAX8PDPK1
SCHEMBL2035163 0.78 HDAC1 (0.33) HDAC1HDAC8HDAC6AOC3MAPT
SCHEMBL15878869 0.78 CA12 (0.40) KDM4EMAPT
SCHEMBL531022 0.78 GAA (0.41) PAX8MT-CO2MAPKAPK2ALDH1A1MAPT
SCHEMBL2636990 0.77 AOC3 (0.33) AOC3
SCHEMBL19470169 0.75 TRPA1 (0.34) HDAC1HDAC8HDAC6PAX8PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 US disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS HDAC1 1897/4885HDAC8 3040/4885HDAC6 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.